论文部分内容阅读
[目的]观察恩度联合TE方案新辅助化疗乳腺癌的临床效果。[方法]23例乳腺癌患者予以恩度联合TE方案新辅助化疗,即:多西紫杉醇(艾素)100mg,d1;表柔比星90mg/m2,d1;恩度15mg/m2,d-7～d-1。2个周期后观察有效率、病理缓解率及新辅助化疗前后微血管密度的变化。[结果]新辅助化疗后临床完全缓解(cCR)者6例,占26.09%;部分缓解(cPR)者14例,占60.86%;病情稳定(SD)者3例,占13.05%;无疾病进展(PD)患者。病理学完全缓解(pCR)者2例,占8.09%。23例患者新辅助化疗后的微血管密度明显降低(P<0.05)。[结论]恩度联合TE方案新辅助化疗乳腺癌后微血管密度明显降低,疗效肯定,值得临床推广应用。
[Objective] To observe the clinical effect of Endue combined with TE regimen neoadjuvant chemotherapy in breast cancer. [Method] Twenty-three patients with breast cancer were enrolled in this study. The combination of neoadjuvant chemotherapy with TE regimen, namely docetaxel 100mg, d1, epirubicin 90mg / m2, d1, Endostar 15mg / m2 and d7 ~ D-1.2 cycles after the observed efficiency, pathological remission rate and neoadjuvant chemotherapy before and after the change of microvessel density. [Results] Six patients (26.09%) had complete clinical remission (cCR) after neoadjuvant chemotherapy, 14 patients (60.86%) had partial remission (cPR), 3 patients (13.05%) had stable disease (SD), and no disease progression (PD) patients. Pathologic complete remission (pCR) in 2 cases, accounting for 8.09%. Twenty-three patients had significantly lower microvessel density after neoadjuvant chemotherapy (P <0.05). [Conclusion] Endovascular combined with TE regimen neoadjuvant chemotherapy for breast cancer significantly reduced the density of microvessels, and the curative effect is worthy of clinical application.